中外制药株式会社 2019H1财报.docVIP

精品资料 精品资料 PAGE / NUMPAGES 精品资料 NOTICE: For the convenience of capital market participants, Chugai makes efforts to provide English translations of the information disclosed in Japanese, provided that the Japanese original prevails over its English translation in the case of any discrepancy found between documentation. CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the second quarter of the fiscal year 2019) Name of Company: Stock Listing: Security Code No.: Representative: Contact: Chugai Pharmaceutical Co., Ltd. July 25, 2019 Tokyo Stock Exchange 4519 (URL ) Tatsuro Kosaka, President CEO Masahiko Uchida, General Manager of Corporate Communications Department +81-(0)3-3273-0881 Phone: Date of Submission of Quarterly Marketable Securities Filings: July 26, 2019 Date on which Dividend Payments to Commence: August 30, 2019 Supplementary Materials Prepared for the Quarterly Financial Statements: Yes Presentation Held to Explain the Quarterly Financial Statements: Yes (for institutional investors, securities analysts and the media) (Note: Amounts of less than one million yen are rounded.) 1. Consolidated results for the second quarter of FY 2019 (January 1, 2019–June 30, 2019) (1) Consolidated operating results Revenues % change Operating profit % change Net income % change 41.2 First six months of FY 2019 First six months of FY 2018 ￥320,285 million ￥285,123 million 12.3 12.8 ￥95,052 million ￥66,569 million 42.8 41.3 ￥69,254 million ￥49,047 million 34.2 Net income attributable to Chugai Total % change comprehensive % change income shareholders First six months of FY 2019 First six months of FY 2018 ￥69,254 million ￥48,672 million 42.3 34.8 ￥67,553 million ￥46,292 million 45.9 28.1 Earnings per share Earnings per share (Diluted) (Basic) First six months of FY 2019 First six